No coin nor oath required. For personal study only.
Biocatalytic solutions are to be jointly discovered and developed by a collaborative venture between DSM Pharma Chemicals and Diversa. The solutions will be designed to cut the cost of various chemical transformations and simplify them. The biocatalysts will be developed by Diversa for chemical transformations identified by DSM Pharma Chemicals. The processes will be scaled up by DSM to manufacturing level. Over 25 industrial production process have already been developed by DSM Pharma Chemicals using enzymatic catalysts.
π SIMILAR VOLUMES
## BASF licenses proprietary enzyme Diversa Corp has granted BASF a licence to a proprietary enzyme for the biocatalytic synthesis of a pharmaceutical intermediate. BASF will manufacture the biocatalyst and use it in one of its processes to synthesise a chiral intermediate. Manufacturing Chemist, M
residual biomass. The US' 75 ethanol refineries produced a record 2.8 bn gallons in 2003. At least 12 new ethanol refineries are being built in the US. This is largely attributable to the development of more efficient enzymes, advances in genetically modified maize, and government subsidies. Approxi
At the Annual General Meeting of Clariant AG, held on 31 Mar 2011, the way was cleared for takeover of more than 95% of the shares in SΓΌd-Chemie AG. Clariant's shareholders voted in favour of a capital increase, which is a basic requirement for takeover of the SΓΌd-Chemie shares by Clariant. Part of